Related Experiment Videos
Capecitabine-induced coronary vasospasm--a case report
Asad A Rizvi1, Peter Schauer, Dariush Owlia
1Division of Cardiology, Department of Medicine, Hartford Hospital, Hartford, CT, USA.
Angiology
|February 5, 2004
Summary
A 70-year-old man experienced coronary vasospasm after starting capecitabine for colon cancer. This is the first reported case linking this newer chemotherapy drug to vasospasm, a known side effect of older fluoropyrimidines.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Metastatic colon cancer requires effective chemotherapy.
- Capecitabine is a widely used oral fluoropyrimidine prodrug.
- Coronary vasospasm is a potential adverse effect of some chemotherapy agents.
Observation:
- A 70-year-old male patient with metastatic colon cancer developed symptoms of coronary vasospasm.
- The patient had no prior history of coronary artery disease or significant risk factors.
- The onset of vasospasm occurred shortly after initiating capecitabine therapy.
Findings:
- This case represents the first documented instance of coronary vasospasm associated with capecitabine.
- While coronary vasospasm is a known side effect of 5-fluorouracil, its occurrence with capecitabine is newly reported.
- The findings highlight a potential cardiovascular risk associated with capecitabine treatment.
Implications:
- Clinicians should be aware of the potential for capecitabine-induced coronary vasospasm, even in patients without cardiac risk factors.
- This case underscores the importance of monitoring for cardiovascular adverse events during chemotherapy.
- Further research may be warranted to elucidate the mechanism and incidence of capecitabine-related vasospasm.